To investigate glucose levels as a risk factor for unrecognized myocardial infarctions (UMIs). DESIGN: Cohort SETTING: Cardiovascular Health Study. PARTICIPANTS: Individuals aged 65 and older with fasting glucose measurements (N=4,355; normal fasting glucose (NFG), n = 2,041; impaired fasting glucose (IFG), n = 1,706; DM: n = 608; 40% male, 84% white, mean age 72.4 ± 5.6).
U p to 45% of initial myocardial infarctions (MIs) are unrecognized (UMIs). 1 They are problematic because they are asymptomatic and are usually detected during a routine electrocardiogram (ECG) after the event. This delayed diagnosis may delay medical management for prevention of future MI.
In 2015, there were more than 84 million adults with impaired fasting glucose (IFG ) and 30.3 million adults with diabetes mellitus (DM) in the US. 2 In individuals with DM, UMIs account for almost 40% of all MIs. 3 Coronary heart disease (CHD) is the leading cause of death in individuals with DM, and this population is at particularly high risk of UMI. 4, 5 Identifying UMI early in the course of CHD may prevent future progression. Although some studies suggest a more benign course for UMIs, 6 more studies suggest that UMIs may confer the same [6] [7] [8] [9] [10] [11] or even higher risk 12, 13 of subsequent cardiovascular events and mortality than a clinically recognized MI. In the United Kingdom Prospective Diabetes Study (UKPDS), 6 UMI at the time of diagnosis of type 2 DM was associated with a 58% greater risk of having a fatal MI and a 31% greater risk of all-cause mortality over a median follow-up of 17 years. Although DM is a known risk factor for UMI, 3, 14, 15 the role of IFG as a risk factor is largely unknown. Almost 40% of individuals who present with their first ST-segment elevation MI are found to have IFG. 16 To explore the relationship between IFG and UMI in elderly adults, we turned to the Cardiovascular Health Study (CHS), 17 a cohort study of participants aged 65 and older. This analysis sought to determine whether IFG is associated with greater risk of UMI. A significant association would mean that the ongoing epidemic of IFG predisposes a substantial number of individuals to greater risk of UMI, which represents a critical public health concern. In addition, CHS provides us with the opportunity to test whether a 2-hour oral glucose tolerance test can forecast UMI.
METHODS

The CHS Population
The methods used in the CHS have been previously described. 17 Briefly, it is an observational study of risk factors for cardiovascular disease in individuals aged 65 and older. Participants were recruited from Medicare eligibility lists in 4 geographical areas. 17 Starting in 1989 and continuing through 1999, 18 participants underwent extensive annual clinical examinations. Measurements included traditional risk factors such as blood pressure and lipids, as well as measures of subclinical disease. At 6-month intervals between clinic visits, and when clinic visits ended, participants were contacted over the telephone to ascertain number of hospitalizations and health status. The primary outcomes were incident CHD, angina pectoris, heart failure, stroke, transient ischemic attack, claudication, and mortality. CHS participants continue to be followed for these events.
Five thousand eight hundred eighty-eight participants were followed through 1999. 18 Of these, 178 who had a Qwave MI on their baseline ECG, 157 who did not have a baseline ECG, 1,154 who had a prior history of coronary artery disease, and 44 with missing fasting glucose data were excluded, leaving a final analytical study sample of 4,355 participants.
Fasting Blood Glucose
Study participants were initially classified into 1 of 3 groups based on the fasting glucose criteria that the American Diabetes Association has established:
19 normal fasting glucose (NFG; fasting glucose level < 100 mg/dL), IFG (fasting glucose level 100-125 mg/dL), and DM (fasting glucose level > 125 mg/dL, former diagnosis of DM, or taking insulin).
Two-Hour Oral Glucose Tolerance Test
Participants without diagnosed DM underwent a 2-hour oral glucose tolerance test. After fasting blood samples were taken, 75 g of oral dextrose was given to the participants, followed by a second venipuncture 2 hours later.
Participants were divided into oral glucose tolerance groups based on the World Health Organization criteria: normal glucose tolerance (NGT; 139 mg/dL), impaired glucose tolerance (IGT; 140-199 mg/dL), and DM (≥200 mg/dL). 20 
Electrocardiography
Standard 12-lead ECGs were digitally acquired (MAC-PC, Marquette Electronics, Milwaukee, WI) at 10-mm/mV calibration and a speed of 25 mm/s. All ECGs were read centrally and visually inspected for technical errors or inadequate quality. Standard 12-lead ECGs were obtained during the baseline examination (1989-90) and annually thereafter.
Unrecognized Myocardial Infarction
UMI was defined as the presence of major Q waves that met the specific standards for the Minnesota code (codes 1-1 through 1-2, except 1-2-8) or the combined presence of smaller Q waves (code 1-2-8 or 1-3) and significant ST-T-wave abnormalities (codes 4-1 through 4-3 or codes 4-2 through 5-3), 21 consistent with previous publications. 22 
Definitions
During the baseline examination, medical histories were taken and physical examinations performed to obtain clinical information, and fasting blood samples and physical measurements were obtained. 23 Resting, seated systolic and diastolic blood pressure were measured using the auscultatory method with the mid-height of the cuff at heart level. 24 The seated (right arm) blood pressure reading was an average of 2 systolic and diastolic measurements with at least 30 seconds between measurements. Hypertension was defined as use of an antihypertensive medication or blood pressure of 140/90 mmHg or greater. Smoking status was divided into 3 groups: never, former, and current (having smoked within past 30 days).
Statistical Analysis
Baseline characteristics were described for NFG, IFG, and DM. Analysis of variance and chi-square tests were performed to test for between-group differences in baseline characteristics, with NFG serving as the reference. P<.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC).
The unadjusted relationship between fasting glucose status and incident UMI was initially described using Kaplan-Meier curves generated to compare survival free from UMI according to fasting glucose category. Participants who had had a clinically recognized coronary event or death were censored at last known ECG before the clinical event. These relationships were further explored and described using crude and adjusted hazard ratios. Cox proportional hazard models were used to adjust for covariates that differed significantly between groups at baseline (age, sex, BMI, hypertension, antihypertensive medication use, total cholesterol, high-density lipoprotein cholesterol, lipidlowering medication use, smoking status).
RESULTS
After exclusions, the study population consisted of 4,355 participants. Their characteristics are shown according to fasting glucose status in Table 1 . They also had significantly lower fasting triglycerides (126, 143, 174 mmol/L, respectively), prevalence of hypertension (47%, 62%, 71%, respectively), and antihypertensive medication use (30%, 41%, 56%, respectively). Participants with DM were more likely than those in the other groups to be male, whereas those with NFG group were more likely to be female. Participants with DM were more likely to be black (25%) than those with NFG (15%). Four hundred fifty-nine participants (11%) experienced an incident UMI. Figure 1 shows the test for trend for UMI in those with NFG, IFG, and DM. Overall, there was a trend for higher incidence of UMI according to glucose status (p = .06). This trend was not significant in women (p = .4 ) or men (p = .09) in stratified analyses.
Over a mean follow-up of 6 years, there were 202 UMIs in participants with NFG, 183 in those with IFG, and 74 in those with DM. Using Kaplan-Meier curves, a doseresponse relationship was observed, with participants with DM having the lowest event-free survival without an UMI and those with NFG having the highest event-free survival without an UMI (Figure 2 ). According to unadjusted Cox proportional hazard models (Model 1), participants with IFG were slightly more likely to have UMI (risk ratio (RR) =1.11, 95% confidence interval (CI)=0.91-1.41, p = .30), and those with DM were 65% more likely (RR=1.65, 95% CI=1.25-2.14, p < .001) ( Table 2 ). With adjustment for age and hypertension status (Model 2) and age, sex, BMI, hypertension status, smoking status, and total cholesterol (Model 3), the risk was attenuated but remained significant for those with DM. When we stratified the models according to sex, women with IFG were not significantly more likely to experience a UMI than those with NFG. Men and women with DM were significantly more likely to have a UMI than those with NFG. After multivariable adjustment, the association remained significant in men only (Table 3) .
Because 
DISCUSSION
This longitudinal analysis found a significant association between DM and UMI but no association between IFG and UMI over 8 years of follow-up. Our data suggest a potential dose-response relationship between glucose status and risk of UMI, with DM associated with the highest risk, followed by IFG and NFG. Although the results of the glucose tolerance test were not significant, the most plausible explanation remains the imprecise nature of the ECG to fully capture UMI. When we compared the patterns between fasting glucose status and the glucose tolerance test, participants with IFG were more closely associated with NFG, while those with IGT behaved more like those found to have DM during their glucose tolerance test, which parallels previous findings about prognostication based on fasting glucose as opposed to glucose tolerance. 25, 26 It can be difficult to appreciate the true burden and scope of UMI because of its asymptomatic or atypical nature. In a multi-ethnic population free of known cardiovascular disease, almost 2% had ECG findings suggestive of MI. 27 During a subsequent cohort-related examination, nearly 6% of those who underwent cardiac magnetic resonance imaging (CMR) had late gadolinium enhancement, which identified previously unrecognized infarcts. 28 In the Irbesartan Diabetic Nephropathy Trial, 14% of MIs during follow-up were unrecognized. 29 The original baseline analysis of UMI in the CHS found that more than 20% of all MIs in elderly adults were UMIs. 22 Other cohort studies, including the Framingham Study, found that one-quarter of all MIs were UMIs. 14, 30, 31 ; in the Atherosclerotic Risk in Communities Study, 45% of MIs were UMIs. 1 Given that DM, hypertension, and aging are all established risk factors for UMI, it should come as no surprise that, as these risk factors become more prevalent, incident UMIs will increase.
Although identification of UMI is challenging, their significance should not be underestimated because most studies have observed an increase in subsequent cardiovascular risk after UMI. 1, 15, [30] [31] [32] [33] In the UKPDS, participants who had had UMI were at greater risk of subsequent fatal MI (HR=1.58) and all-cause mortality (HR=1.31) than those who did not have UMI. 6 Findings from the Rotterdam Study found that the long-term prognosis in individuals with UMI was worse than those without MI. In certain subgroups, such as men, the clinical events and survival after an UMI was no different from that of a recognized MI. 7 In a study of UMI in the ICELAND MI cohort of elderly participants, UMI detected using CMR was associated with an 8% greater absolute risk of mortality over a median followup of 6.4 years. 33 In an older population, those with UMI had the same mortality as those with a recognized MI. 22 A study of individuals without prior MI undergoing CMR found that those with UMI were 7 times as likely to have a subsequent cardiovascular event or to die. 8 Subsequent studies in the same group showed that those with DM and UMI were 4 times as likely to have a cardiovascular event or to die as those with UMI and no diabetes. 34 One possible mechanism underlying the asymptomatic nature of many UMIs may be neuropathic (peripheral neuropathy or cardiac autonomic neuropathy (CAN)), particularly in people with DM. 35 It is likely that DM contributes to UMIs through cardiac autonomic neuropathy, 36 which may lead to a loss of pain sensation. 37 One such example of this pathophysiology has been in people with DM who have radiographic evidence of significant osteoarthritis yet report little pain. 38 In the Tromso Study, investigators conducted cold pressor tests on 4,849 participants; 8% had UMI, and 4.7% had recognized MI. Subjects with UMI endured the cold pressor test significantly longer than those with recognized MI, indicating less sensory perception. When stratified according to sex, this association was statistically significant only in women. 39 Another study found that neuropathic pain and polyneuropathy were more common in participants with IGT than in those with NGT. 40 A subsequent study found that individuals with MI with IGT were more likely to have neuropathy than those with NGT. 41 Although neuropathic pain in individuals with IGT and IFG tends not to be as severe as in those with DM, the first fibers affected are small sensory nerves. Loss of sensory function 42, 43 may occur along with other adverse pathophysiological changes that occur during the prediabetic phase, including hyperglycemia, microvascular abnormalities, dyslipidemia, hypertension, and other factors associated with the metabolic syndrome. 44 These factors increase risk of UMI and may be present for many years before diagnosis. Approximately 11% to 25% of individuals with IFG have peripheral neuropathy, 37 and more than 25% of those with IGT were identified as already having manifestations of autonomic dysfunction in the Finnish Diabetes Prevention Study, 45 which may increase the risk of UMI. 42, 46 In a meta-analysis, the prevalence of MI in individuals with DM was twice as high in those with CAN as in those without (Odds Ratio: 1.96 , 95% CI=1.53-2.51). 47 Mechanistically, adrenergic innervation defects and lower heart rate variability are more common in individuals with IFG than in those with NFG, 48 supporting this hypothesis. Several questions can help guide clinicians in developing strategies to explore the relationship between IFG and UMI. First, which strategy would best serve to screen for UMI? Although CMR is the criterion standard in infarct imaging for UMI, 33 it is not widely available and is costprohibitive on a public health scale. Although screening ECGs may not be as sensitive as CMR in detecting UMI, they are a highly cost-effective method of detecting MI. 49, 50 Conversely, because neuropathy seems to be underdiagnosed, should screening for neuropathy be performed to determine who should undergo screening for UMI? Although there are many parallels between recognized MI and UMI, it is unclear at this point which intervention would serve best specifically to prevent UMI except for effective risk factor modification. Although IFG was not independently associated with UMI in this elderly cohort, it may have resulted from significant age-related glycosylation, which would mean that their blood vessels already have significant glucose exposure. 51 There are limitations to this study. A limiting factor in our analyses was the use of the 12-lead ECG to identify UMI. Recent studies have suggested that other diagnostic means, such as CMR, are more sensitive in detecting UMI, 28, 33 but CMR is logistically impractical and expensive. Our sample size may not have been large enough to detect an association between IFG or IGT and UMI using primarily ECG. In addition, statin use is much more prevalent today than at the time these data were collected.
PUBLIC HEALTH IMPLICATIONS
Prevention remains the best strategy to mitigate the cardiovascular risks and mortality associated with UMI. The rising prevalence of IFG means that a substantial portion of the general population is at risk of cardiovascular problems. The prevalence of IFG is increasing in the developed and developing world. 52, 53 In the United States, the prevalence of IFG has increased substantially over the past 20 to 30 years. In the mid-1990s, almost 15% of people had IFG. By the late 2000s, this had risen to almost 30%. In older individuals, the prevalence of IFG is greater than 40%. Although much of the risk associated with IFG is attributed to the progression to DM, 54 this study highlights that significant clinical pathology can and does exist in those with IFG.
Although we did not find a significant association between IFG and UMI over 6 years of follow-up, there is a dose-dependent relationship between fasting glucose level and UMI. Given the substantial increase in estimated incidence rates of UMI, it may be useful to investigate IFG as an indicator to screen for UMI in larger sample size. The extremely high prevalence of IFG (35-50%) 55, 56 in adults worldwide may further justify such an effort. In the universe of prevention of heart disease, the enormous population at risk of DM is an extremely important target for public health efforts to detect and prevent heart disease.
CONCLUSION
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